Previous Article | Next Article 
Journal of Virology, March 2000, p. 2239-2246, Vol. 74, No. 5
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Membrane-Proximal Stem Region of Vesicular
Stomatitis Virus G Protein Confers Efficient Virus Assembly
Clinton S.
Robison and
Michael A.
Whitt*
Department of Microbiology and Immunology,
University of Tennessee
Memphis, Memphis, Tennessee 38163
Received 13 September 1999/Accepted 7 December 1999
 |
ABSTRACT |
In this report, we show that the glycoprotein of vesicular
stomatitis virus (VSV G) contains within its extracellular
membrane-proximal stem (GS) a domain that is required for efficient VSV
budding. To determine a minimal sequence in GS that provides for
high-level virus assembly, we have generated a series of recombinant
G-VSVs which express chimeric glycoproteins having truncated stem
sequences. The recombinant viruses having chimeras with 12 or more
membrane-proximal residues of the G stem, and including the G protein
transmembrane-cytoplasmic tail domains, produced near-wild-type levels
of particles. In contrast, viruses encoding chimeras with shorter or no
G-stem sequences produced ~10- to 20-fold less. This budding domain
when present in chimeric glycoproteins also promoted their
incorporation into the VSV envelope. We suggest that the G-stem budding
domain promotes virus release by inducing membrane curvature at sites where virus budding occurs or by recruiting condensed nucleocapsids to
sites on the plasma membrane which are competent for efficient virus budding.
 |
INTRODUCTION |
Vesicular stomatitis
virus (VSV) is a relatively simple enveloped RNA virus from the
Rhabdoviridae family that assembles at the plasma membrane
of a host cell and is released from the cell by a process called
budding. VSV virions consist of a helical ribonucleocapsid (RNP) core,
which contains the single-stranded, nonsegmented, negative-sense RNA
genome tightly encapsidated by 1,258 molecules of the nucleocapsid (N)
protein (45). The viral polymerase, which consists of the
phosphoprotein (P) and the large catalytic subunit (L protein), is also
tightly associated with the RNP in virions. Prior to budding, the
nucleocapsid core condenses upon binding to the matrix (M) protein.
Initiation of virus budding occurs when the condensed core associates
with the inner leaflet of the plasma membrane, presumably through M
protein-dependent interactions (6, 18). During budding, the
condensed core becomes enclosed within a membrane envelope that
consists of host-derived lipids and approximately 1,200 molecules of
the VSV spike glycoprotein (G protein) (45).
Although much progress has been made in defining domains that are
important for the assembly and release of virions from the cell
surface, as well as for glycoprotein incorporation into virions, relatively little is known about what drives the budding process. For
example, studies examining the role of glycoprotein cytoplasmic tails
(CTs) in the assembly of a variety of enveloped viruses have provided
evidence that the tails are indeed important but often not essential
for virus assembly or infectivity (1, 9, 14-16, 28, 30, 39,
47). In contrast, it has been shown that there is an absolute
requirement for the CT of alphavirus glycoprotein in alphavirus
assembly and budding (5, 19, 24, 32, 43). At the other
extreme, many retroviruses (8, 11, 34, 46) and now
rhabdoviruses (28, 44) have been shown not to require viral
glycoproteins at all for the assembly and release of virus particles.
It is likely that interactions of the late domains, found within
rhabdovirus M or retroviral Gag proteins, with host factors at the
plasma membrane are the primary driving force in budding and release of
particles (7, 12). In the case of rhabdoviruses, typical
bullet-shaped virions are produced from cells infected with recombinant
viruses that either lack G protein (
G viruses) (28, 44)
or express heterologous glycoproteins in the absence of G protein
(17, 41). However, the amount of
G virus released is
significantly less than that released from wild-type
(WT)-virus-infected cells, suggesting that G protein contributes to the
efficiency of virus budding.
To examine the requirements for VSV assembly and budding, we have taken
a reverse genetics approach and have generated several different
recombinant VSVs that encode either truncated or chimeric envelope
proteins. The goal of these studies is to understand which components
of the virion are essential for high-level virus budding and what
factors influence the efficiency of glycoprotein incorporation into
virions. In this report, we show that a relatively small domain in the
membrane-proximal stem region of the G protein ectodomain contributes
to efficient G protein incorporation and virus budding. We suggest that
the G-stem domain contributes directly to high-level virus budding
either by facilitating membrane curvature at the bud site or by
selecting subdomains of the plasma membrane that are competent for
virus release, perhaps by modifying the local lipid environment such
that efficient virus release occurs.
 |
MATERIALS AND METHODS |
Recombinant cDNAs.
The construct GSHA (G-stem
hemagglutinin epitope [HA] tagged), which encodes a truncated version
of VSV G protein, was generated by PCR-mediated mutagenesis using a
sense primer that overlapped the MluI site in the 5'
nontranslated region of the G protein gene of pVSVFL(+)-2 and an
antisense oligonucleotide,
5'-AGGATGTTCGAAAGCGTAATCTGGTACATCATACGGATACTTGCAATTCACCCCAATG-3', which overlapped the NspV site (underlined) at
position 1280 in the G protein gene. The antisense primer linked
sequences encoding a portion of the G protein signal peptide (in
italics) to the HA epitope (in boldface) followed by the
membrane-proximal stem region of the G protein ectodomain. The amplicon
was digested with MluI and NspV and then
subcloned into pBS-GMMG (42), which had been digested with
the same two enzymes. A similar construct, GS (G stem), which did not
contain the HA epitope, was also generated using the appropriate
mutagenic primer. The sequences were confirmed by dideoxynucleotide
sequencing. The GSHA or GS fragments were then moved into
pVSV-FL(+)-2 (21) by replacing the G gene using the
MluI and NheI sites.
The CD4-G chimeras were constructed by PCR-mediated mutagenesis using,
individually, a series of sense-strand oligonucleotides that had a
common 5' sequence (5'-ATGGCCTCGGGT...) which
contained an AvaI site (underlined) followed by sequences
coding for amino acids starting at Q427, P434,
F440, S447, V454, and
F458, respectively (complementary sequences are indicated
by ...), and an antisense oligonucleotide,
5'-CCAAACATGAAGCTTCTGTTGTGCATGCTTTGAGTTAC-3', which introduced an SphI site (underlined) within the
3' untranslated region of the GInd cDNA. In-frame chimeras
were produced by ligation of a XhoI-AvaI fragment
encoding the ectodomain of human CD4, with the various
AvaI-SphI fragments encoding GS peptides of
varying lengths (illustrated in Fig. 1).
Also, similar CD4 constructs, E422 and
G404-link, were produced by in-frame ligations of the CD4-encoding XhoI-AvaI fragment to either a
naturally occurring NspV site or a naturally occurring
KpnI site in the G-encoding sequence (at amino acid
positions 422 and 404, respectively) by using either an
AvaI-NspV- or an
AvaI-KpnI-compatible double-stranded oligonucleotide linker that encoded amino acid residues GASKAQV or
AGGGSGGGGST, respectively.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of membrane-proximal regions of the VSV
GI ectodomain, and chimeras containing heterologous
sequences derived from the ectodomains of human CD4 or influenza virus
HA. The top schematic represents the stem region of G protein (GS),
with numbers below the amino acid sequence of the ectodomain (ecto)
indicating the distance in residues from the TM domain (boxes) and
where residue numbering above the stem indicates their position from
the N terminus of G protein. This nomenclature is used for the CD4
chimeras to indicate the position of G protein that was linked to the
CD4 ectodomain. Representation of chimeric domain composition is shown
at left, where domains encoding heterologous sequences are in dark
boxes.
|
|
A full-length
G-VSV cDNA was generated by replacing the WT G protein
gene in pVSVFL(+)I/NJG (21) with an
oligonucleotide-derived polylinker region
(5'-MluI-KpnI-XhoI-SmaI-EagI-SphI-NheI-3')
introduced between the MluI and NheI sites of
pVSVFL(+)I/NJG. This plasmid (pVSV
G-PL) was used to
generate the recombinant VSV cDNAs encoding either GS,
GSHA, or the CD4-G chimeras described above. A six-gene VSV
cDNA, which had an additional transcription unit placed between the G
and L genes, was also generated. This construct, called
pVSV-
G-GSHA/GFP, expressed GSHA from the
upstream transcription unit and green fluorescent protein (GFP)
(3, 13) from the adjacent downstream transcription unit
located immediately before the L gene.
Production of recombinant VSV.
Recovery and propagation of
infectious
G viruses were similar to those described previously
(44). Approximately 106 BHK-21 cells in
35-mm-diameter dishes were infected with a recombinant vaccinia virus
encoding bacteriophage T7 RNA polymerase at a multiplicity of 5 for 40 min. The cells were then transfected with a DNA-liposome suspension
composed of 5 µg of the appropriate pVSV-
G plasmid and 8, 3, 5, and 1 µg of plasmids containing the WT G, N, P, and L genes,
respectively, from the Indiana serotype of VSV (VSVInd). Cationic liposomes used for the transfections were prepared as described previously (2, 35). After 4 h, the
transfection mix was replaced with Dulbecco modified Eagle's medium
(DMEM) containing 10% fetal bovine serum. At 48 h
posttransfection, the supernatants were harvested and filtered through
a 0.2-µm-pore-size filter (Millex-GS; Millipore) to remove vaccinia
virus. The filtrates were applied to 106 BHK-21 cells
transiently expressing G protein. For transient expression of G
protein, we used pCVSVG (44). Approximately 7 × 105 BHK-21 cells were transfected with a DNA-liposome
suspension composed of 10 µl of Lipofectamine (Gibco-BRL) and 2 µg
of pCVSVG in 2 ml of OptiMEM (Gibco-BRL) according to the
manufacturer's instructions. After 8 to 12 h, the transfection
mix was replaced with DMEM containing 10% fetal bovine serum.
Filtrates were added to the cells at 36 h posttransfection. Cells
were examined for cytopathic effects typical of VSV infection after 24 to 72 h. The recombinant viruses were then plaque purified on
cells transiently expressing G protein and subsequently passaged on
G-expressing cells to produce high-titered infectious stocks
(~108 to 109 IU/ml). Titers were determined
using an immunofluorescence-based assay. Cells were infected with
limiting dilutions of virus supernatants and fixed with 3%
paraformaldehyde at 12 to 18 h postinfection, and the number of
infected cells was determined by indirect immunofluorescence using
anti-M protein-specific (23H12) or N protein-specific (10G4) monoclonal
antibody (23). Viral expression of the foreign or chimeric
proteins was verified for the individual clones and for passaged virus
stocks by indirect immunofluorescence using either a CD4-specific
monoclonal antibody (Sim.2 [25] obtained from the
National Institutes of Health AIDS Research and Reference Reagent
Program), an HA epitope-specific monoclonal antibody (12CA5, kindly
provided by Lorraine Albritton, University of Tennessee
Memphis), or
an A/Japan HA-specific goat polyclonal serum (kindly provided by Robert
Webster, St. Jude Children's Research Hospital).
The
G-GSHA virus was recovered by an alternative
strategy in which a VSV minivirus (GMMG) expressing only the G and M
proteins (42) was used to provide the source of
complementing G protein. Approximately 106 vTF7-3 infected
cells were transfected with 10 µg of pVSV-
G-GSHA and
3, 5, and 1 µg of plasmids encoding the WT VSVInd N, P,
and L proteins, respectively. The transfection mix was removed after 3 h, and the cells were then superinfected with GMMG particles at
a multiplicity of infection (MOI) of 1. Fresh medium was added directly
to the cells after they adsorbed the GMMG minivirus for 1 h.
Supernatants were harvested 18 h later and then filtered to remove
vaccinia virus. One-half of each filtered supernatant was used to
infect fresh cells. Successful recoveries were indicated when cultures
showed the typical cytopathic effects of a normal VSV infection after
18 to 24 h. The titers of the supernatants from those cultures
were then determined, and stocks of the cocomplementing viruses were
produced by infecting fresh cells at an MOI of 0.01. Supernatants,
which contained both
G-GSHA and GMMG, were harvested
after 24 h, and the two particles were concentrated by
centrifugation and then separated by banding in 20 to 45% sucrose
gradients. The lower fraction, which usually contained approximately
300-fold-more
G-GSHA than GMMG, was recovered by side
puncture, and the proportion of
G-GSHA to GMMG was
determined by an immunofluorescence-based titering assay utilizing
either an N protein-specific (for
G-GSHA) or a G
protein-specific monoclonal antibody (I1) (23). To obtain a
stock of
G-GSHA which was free of GMMG, the partially
purified
G-GSHA fraction was used to infect cells
expressing the G protein from the New Jersey serotype of VSV
(GNJ) and then neutralizing antibody, which was specific
for the Indiana serotype of VSV (VSVInd), was added to the
culture medium. The amount of Indiana-specific serum used completely
neutralized all virus produced by
G-GSHA-GMMG-coinfected cells. After three consecutive
passages on cells expressing GNJ and in the presence of
anti-VSVInd neutralizing antibody, the titers of
G-GSHA reached approximately 108 IU/ml while
0.5 ml of the supernatant contained no detectable GMMG. High-titered
stocks of pure
G-GSHA complemented with the
GInd protein were then made as described above for the
CD4-G chimeric
G viruses.
Virus budding assay.
BHK-21 cells were infected with either
WT VSV or the G-complemented
G viruses at an MOI of 10 for 1 h,
washed three to four times with DMEM, and incubated in serum-free DMEM.
At 18 h postinfection, virions were purified from the supernatants
by centrifugation through a 20% sucrose cushion in an AH650 rotor at
45,000 rpm for 35 min. The pellets were suspended in equal volumes of
reducing sample buffer, and one-third of each sample was resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by colloidal Coomassie blue staining (Gel Code Blue; Pierce
Chemical Co.). Virus yields were determined by quantifying N protein
content using ImageQuant analytical software (Molecular Dynamics) from
digital images of the stained gels captured using transmitted light.
Metabolic labeling of viral protein.
The CTs of WT
GI protein, GSHA, HA-G, and the CD4-G chimeras
were labeled with [3H]palmitate by infecting 2 × 106 BHK-21 cells with the appropriate viruses at an MOI of
10 for 1.5 h. Following infection, the cells were washed twice
with DMEM, and then DMEM supplemented with 1.5% dimethyl sulfoxide and
2.5 mCi of 9,10-[3H]palmitate was added. Virions were
purified from the supernatant as described above, and one-half of each
of the samples was resolved on a 10 to 20% polyacrylamide gradient
SDS-PAGE gel followed by fluorography.
Chemical cross-linking studies.
Samples containing
approximately 250 ng of purified virions were incubated with DTSSP
[dithiobis(sulfosuccinimidylpropionate)] at final concentrations
ranging from 0 to 200 µM in 5 mM sodium citrate (pH 5.5) for 30 min
on ice. The reactions were quenched by making the solution to 50 mM
glycine. Approximately 1/10 of each sample was resolved by nonreducing
SDS-PAGE and transferred to a polyvinylidene difluoride membrane.
Immunoblotting was carried out using anti-G CT-specific polyclonal
rabbit sera, followed by chemiluminescent detection using the ECL
reagent (Pierce) according to the manufacturer's instructions.
 |
RESULTS |
Assembly phenotypes of recombinant
G-VSVs.
Previous studies
by others using recombinant VSVs that expressed heterologous
glycoproteins, either in the presence or in the absence of WT G
protein, had found that some foreign glycoproteins could be
efficiently incorporated into VSV particles, while others could not
(17, 20, 40, 41). These results suggested that heterologous
glycoprotein incorporation is not dependent on the presence of G. However, the amount of rhabdovirus particles produced in the absence of
G protein was significantly less than that when G protein was expressed
(28, 41). Therefore, G protein contributes to the efficiency
of virus budding. To understand the basis for this phenomenon, we set
out to first identify domains in G protein that contribute to
high-level virus budding as seen during a WT VSV infection.
To examine the contribution of the transmembrane (TM) and CT domains in
virus budding and glycoprotein incorporation, we produced several
different recombinant VSVs in which the G gene was replaced by those of
heterologous or chimeric proteins. To examine virus budding in the
absence of a virus-encoded glycoprotein, we used a recombinant VSV
described previously (44) called
G*, which has the G gene
replaced with that encoding GFP. Figure 2
shows the results from recombinant viruses that encode either CD4 or a
chimera composed of the CD4 ectodomain fused to the TM and CT of G
(CD4-G). In Fig. 2A, viruses encoding either CD4-G, CD4, or GFP (no G
protein) produced approximately 10- to 20-fold-fewer particles than WT
VSV. These data indicate that the TM-CT of G protein is not sufficient
to drive efficient virus budding, in the context of the CD4 ectodomain,
nor do these domains enhance incorporation of CD4-G relative to that of
CD4. Therefore, the ectodomain, or a region within the ectodomain, must
contribute to high-level virus budding and efficient envelope protein
incorporation as seen for WT VSV.

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 2.
Budding efficiency and glycoprotein incorporation. (A)
Cells infected with recombinant G-VSVs were metabolically labeled
with [35S]methionine, and virus released into the
supernatant was purified by ultracentrifugation. The viral pellets were
resuspended in identical volumes of reducing SDS sample buffer, and
proteins were resolved by SDS-PAGE followed by Coomassie blue staining.
Shown is a Coomassie blue-stained gel on which equivalent sample
volumes were loaded (corresponding to one-third of the virus produced
from 106 cells). The same gel was used for autoradiography
and resulted in a protein profile indistinguishable from that shown in
the figure. (B) Similar amounts of viral protein were loaded per lane
as determined by 35S radioactivity. Quantitation of viral
proteins was determined using a STORM phosphorimager and ImageQuant
software. Virus yields were calculated from the signal intensities
produced by N, P, and L proteins, either in sum or separately, and
percentages were determined relative to the values obtained for WT
VSV.
|
|
Characterization of the membrane-proximal G stem.
To determine
if we could identify a region in the G protein ectodomain that promotes
high-level virus production, we generated a virus that expressed a
truncated form of G protein that has the 42 membrane-proximal residues
of the G ectodomain plus the TM anchor and CT. We call this protein G
stem (GS) for simplicity. The rationale for designing this construct
was based on reports that membrane-anchored proteolytic cleavage
products of G are transport competent and are incorporated in virions
(4). These C-terminal proteolytic fragments were once
thought to be essential for the budding of spikeless (or bald)
ts045 virions produced at the nonpermissive temperature
(29). To determine if GS was expressed on the cell surface,
we constructed GSHA by replacing ~90% of the ectodomain
with a nine-residue N-terminal HA epitope tag at position
F421 (Fig. 1). Cells transiently expressing GSHA showed bright surface staining when examined by
indirect immunofluorescence microscopy using the HA-specific monoclonal
antibody 12CA5, indicating that GSHA was transported to the
plasma membrane. The GS or GSHA cDNAs were inserted into
G-PL to create
G-GS or
G-GSHA, respectively. A
third virus, called
G-GSHA*, which expressed GFP from a
sixth VSV transcriptional unit placed between the GSHA and
L protein genes, was also produced.
In contrast to the CD4 recombinants,
G-GSHA-infected
cells produced near-WT amounts of virus (Fig. 2A, lane 2). The results from multiple independent experiments indicated that virus yields for
G-GSHA ranged from 70 to 80% of WT level, whereas the
yields for
G*,
G-CD4, and
G-CD4G ranged from approximately 5 to 10%. The amounts of CD4 or CD4-G in purified virions were virtually
identical, ranging from 14 to 18% of that found for G protein when
normalized to N protein and for methionine content (Fig. 2B; see also
Fig. 6 legend).
Envelope protein oligomerization and effects on virus
assembly.
Considering that CD4 is a monomer and G protein is a
trimer, we next asked if GSHA is also oligomeric, and if
so, could this be the natural context by which spike proteins promote
efficient assembly of VSV particles? To address whether GS has the
potential to form oligomers, we conducted chemical cross-linking
analysis using a membrane-impermeable reagent (DTSSP). As shown in Fig.
3, GSHA could be cross-linked
into species migrating at the molecular weights expected for dimeric
and trimeric forms of the protein. Similar experiments were also
conducted using the membrane-permeable cross-linking reagent DSP
[dithiobis(succinimidylpropionate)]. Similarly, we found that
GSHA dimer and trimer species were also observed with
increasing DSP concentrations (data not shown).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 3.
Chemical cross-linking analysis of the G stem. Purified
virions were subjected to increasing concentrations (0, 10, 100, and
200 µM) of the membrane-impermeable cross-linking reagent DTSSP.
After quenching of the reaction, the samples were resolved by SDS-PAGE
under nonreducing conditions and detected by immunoblotting using
anti-G CT-specific polyclonal rabbit sera. The GSHA
molecule is shown to be similar to WT G protein in its ability to be
chemically cross-linked into species that migrate at the approximate
molecular masses expected for their dimeric and trimeric forms.
|
|
Since the G stem appears to be an oligomer, we next wanted to determine
if the TM and CT domains, when presented in the context of a trimer,
could drive high-level virus budding. To test this hypothesis, we
constructed recombinant
G-VSVs that expressed influenza virus HA-G
protein chimeras (Fig. 1). These chimeras had previously been shown to
fold, oligomerize, and be transported to the cell surface similar to
WT-HA (22, 36). The three constructs that we examined were
composed of (i) the ectodomain of HA fused to the TM-CT of G
(HAG2, previously referred to as HA-G-G
[22]), (ii) the ectodomain-TM of HA fused to the CT of
G (HA2G, previously referred to as HA-HA-G
[22]), and (iii) the ectodomain of HA fused to amino
acid 451 of G, which corresponds to the 12th membrane-proximal residue
of GS, as well as the TM-CT of G (HAG [36]). When
these viruses were grown in cells that did not express G protein, but
in the presence of trypsin and neuraminidase, we found that infectious
particles were released. This indicated that the HA-G chimeras were
functionally incorporated into the VSV envelope. The protein profiles
of the HA-G chimera-expressing
G-VSVs are shown in Fig.
4. Cells infected with viruses that expressed the HA chimeras containing either the TM-CT
(HAG2) or only the CT of G protein (HA2G)
produced less than 5% of the amount of virus released by WT VSV-infected cells. These data show that the TM-CT or only the CT
domains of G, when presented under the structural constraints of an HA
trimer, are not sufficient to drive high-level budding. Furthermore,
these results demonstrate that the TM and/or CT does not directly
confer any positive effect on virus release or glycoprotein incorporation in the absence of the G ectodomain. In contrast, when
cells were infected with the
G-HAG virus, which has 12 TM-proximal residues of GS together with the TM-CT of G, particle production increased approximately 20- to 30-fold over that produced by the HAG2 or HA2G virus. The results indicate that
as few as 12 membrane-proximal residues of GS, in the context of an
HA-G chimera, are sufficient to facilitate high-level virus budding.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 4.
Virus produced by recombinant viruses expressing
oligomeric spike proteins. Virions budded in the absence or presence of
neuraminidase (NA) by viruses expressing chimeras consisting of either
the ectodomain of HA plus 12 membrane-proximal residues of the G
stem-TM-CT (HAG), the ectodomain of HA plus the G TM-CT
(HAG2), or the ectodomain and TM of HA plus the G CT
(HA2G) (Fig. 1) were compared to those of WT VSV and
G-GS. Viral proteins were analyzed by loading equivalent volumes and
resolving them by SDS-PAGE. The gel was Coomassie blue stained and
photographed with transmitted light using a digital camera. Virus
yields were determined by quantitation of the N protein-containing
bands using ImageQuant software and calculated as a percentage of WT
VSV N protein content. L protein and P protein content were also
calculated and found to closely agree with the results for the N
protein analysis.
|
|
Effects of G-stem truncations on virus assembly and budding.
We next wanted to determine a minimal sequence within GS that was
sufficient to confer high-level virus budding. To address this
question, we generated a series of
G-VSVs that expressed chimeric
glycoproteins composed of the CD4 ectodomain fused to N-terminally
truncated G stems (Fig. 1). By transient transfection, these chimeras
were found to be expressed on the cell surface at levels comparable to
those of CD4 or CD4-G. When cells were infected with recombinant
viruses expressing CD4 chimeras that possess either 9, 5, or 0 membrane-proximal GS residues (V454, F458, or
CD4-G, respectively),
G* or basal levels of particles were produced.
This corresponded to approximately 5% of the particles produced by WT
VSV (Fig. 5). In contrast, the amount of
virus released in the context of chimeras containing at least 16 GS residues was approximately 10- to 20-fold higher than the
G* levels.
From multiple experiments, this corresponded to near-WT production
levels (between 40 and 80%). Together with the HA-G chimera data,
these results demonstrate that in the context of heterologous
glycoprotein chimeras the membrane-proximal 12 to 16 residues of the G
ectodomain are sufficient for high-level virus budding.

View larger version (72K):
[in this window]
[in a new window]
|
FIG. 5.
Virus budded from cells infected by recombinant
G-VSVs expressing CD4 chimeras containing truncated stem sequences.
Virions released from cells infected with viruses expressing CD4
chimeras having different-length stem sequences were compared to those
of either WT VSV or G-GSHA (*, see Fig. 1 for
details). Virions were prepared as described in the text, and virus
pellets were suspended in identical volumes of sample buffer. Viral
proteins were analyzed as described for Fig. 4.
|
|
It seemed likely that a budding domain of an envelope protein would
also facilitate its efficient incorporation into the viral envelope. As
shown in Fig. 6, the GS and HAG proteins
were efficiently incorporated into virions at about 80 to 90% of the
level of G. However, it appeared that the assembly-proficient CD4-GS
chimeric glycoproteins were not incorporated nearly as well as WT G or HAG (Fig. 4 and 5). This was unexpected, since our assumption was that
efficient incorporation of a membrane-spanning protein would be
associated with that protein's ability to promote high-level virus
budding. Upon initial examination by Western blot analysis, using
CT-specific antisera, we found that the CD4-GS chimeras were
incorporated into virions as full-length glycoprotein and as C-terminal
processed fragments (data not shown). Similar results for metabolically
labeled proteins are shown in Fig. 6. The
[3H]palmitate-labeled products of the CD4-GS molecules
are heterogeneous in size as a result of cleavage near the CD4-GS
junction. The full-length glycoprotein and material of approximately 12 to 16 kDa (similar in size to GS) were incorporated, indicating that the envelope contains both species (e.g., cleaved GS and full-length CD4-GS). Although small amounts of these low-molecular-weight species
were also observed in WT VSV virions, they were completely absent from
HAG and CD4-G virions. Thus, it appears that the processing event(s)
leading to the generation of GS fragments is not obligatory for
high-level virus budding or glycoprotein incorporation.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 6.
Incorporation of assembly-proficient or
assembly-deficient spike proteins into VSV virions. The cytoplasmic
tails of the spike proteins were metabolically labeled with
[3H]palmitic acid and analyzed as described in the text.
Identical volumes of samples were loaded onto a 10 to 20% gradient
gel, electrophoresed, and then fluorographed. The amount of spike
incorporated (shown as a percentage of that for G) was determined after
normalization to N protein content. The percentages of G incorporation
were calculated from similar signal intensities using different
exposure times of the fluorographs. The total values shown are for the
processed and unprocessed forms of those proteins in which cleavage
occurs; HAG(0) uncleaved and
HAG(2) furin-processed C termini, or the
full-length and C-terminal fragments of CD4-S447 and
-V454 were combined to give an incorporation level for both
species.
|
|
 |
DISCUSSION |
Previous reports have demonstrated that rhabdoviruses can bud in
the absence of virally encoded glycoproteins (28, 44). However, the number of virus particles released from
G-infected cells was significantly less than that made by WT virus. For example,
G-rabies virus (RV) produced 30-fold-less virus (28) than
did the parental WT virus. In the case of some
G-VSVs which encoded foreign glycoproteins, approximately 50-fold-fewer particles than from
the comparable WT counterpart were released (41). Although the amount of virus released from
G-infected cells was significantly reduced, these initial studies provide the first direct evidence that
the minimal components needed to initiate, drive, and complete the
budding process are the condensed RNP core in association with the
matrix (M) protein. Furthermore, these findings indicated that the
mechanism of rhabdovirus budding is probably more like that of type C
retroviruses, which also do not require viral glycoproteins to release
particles (reviewed in reference 10). In fact, these different types of viruses share similar proline-rich domains (PPxY
motif in rhabdoviral M and late domain of retroviral Gag), which have
recently been implicated to be the primary driving force in particle
budding (7, 12). However, it is clear that rhabdovirus
budding in the absence of the WT glycoprotein is inefficient; therefore, the envelope glycoprotein contributes to virus release. Similar findings have recently been reported for baculoviruses, where
efficient budding is dependent on the presence of the major envelope
glycoprotein, GP64 (31).
In this report, we analyzed the budding phenotypes of several different
recombinant
G-VSVs to identify regions of G protein that are
essential for high-level assembly and budding. We found that the TM and
CT domains of G are not sufficient to promote high-level virus budding
even when the TM and CT are presented in the context of a trimer.
Recombinant viruses expressing either CD4, CD4G, or the two HA-G
chimeras (HA2G and HAG2) produced the same
amount of virus as did
G-VSV. Although the recombinant VSVs that we
used differ from those used by Schnell et al. (39), our
findings corroborate their conclusions that the TM and CT domains, per
se, are not the primary determinants of G protein that contribute to
virus budding or to glycoprotein incorporation into virions. In this
respect, VSV differs from RV in that foreign glycoprotein incorporation
appears to require the RV G protein TM and CT domains (26,
27). The basis for these alternative requirements is currently
not known, but what has emerged from these studies is that glycoprotein
assembly into RV appears to be quite stringent. In contrast, VSV
appears to be more promiscuous and can utilize a variety of different
TM and CT sequences. Although there is no specific sequence requirement in the VSV CT domain, there is a strong requirement for the presence of
at least a short sequence of amino acids to promote budding (39). The observation that oligomerization of the TM-CT
domains of G was not sufficient to restore high-level budding of
virions was somewhat unexpected, since models of virus budding propose that interactions (whether specific or nonspecific) between the CT and
components of the condensed nucleocapsid ostensibly are important to
initiate or to drive virus budding. Instead, we found that a C-terminal
portion of G, containing a relatively small region in the
membrane-proximal stem of the G protein ectodomain in conjunction with
its TM and CT domains, was the primary determinant for promoting
efficient virus budding.
There are now several examples where extracellular domains have been
shown to be critical for glycoprotein incorporation into virions. In
the case of the influenza virus M2 ion channel, a signal within the
extracellular domain has been identified which mediates incorporation
of M2 into influenza virus particles (33). Furthermore, M2
appears to be important for incorporation of other influenza virus
envelope proteins into virions. Therefore, the ectodomain of M2 may
serve in targeting the viral spikes to regions of the plasma membrane
where virus particles are actively budding, rather than participating
directly in the budding process. Another example where the ectodomain
of a viral spike protein is critical for its incorporation into virions
is the hydrophobic, tryptophan-rich region of the membrane-proximal
domain of human immunodeficiency virus type 1 (HIV-1) gp41
(37). Not only is the highly conserved tryptophan-rich motif
in gp41 important for viral glycoprotein incorporation into HIV
virions, but also it is vital for fusogenic activity. In recent
studies, we have found that the VSV GS can enhance or potentiate the
membrane fusion activity of a variety of different viral fusion
proteins (C. S. Robison and M. A. Whitt, 18th Annu. Meet. Am.
Soc. Virol., abstr. W32-10, 1999). This suggests that, for VSV G
protein, and possibly HIV gp41, the membrane-proximal domain may be the
critical link between two opposing but related activities (e.g., virus
budding and virus entry).
The importance of the G protein membrane-proximal domain for virus
assembly and release was initially demonstrated by the phenotypes of
viruses expressing membrane-anchored GS proteins. Since the GS proteins
contained less than 10% of the ectodomain, it was remarkable that such
a small region was able to drive virus budding to levels similar to
that conferred by WT G protein. The results from both the CD4 and HA
chimeric viruses further demonstrated that a subdomain of GS necessary
to promote high-level budding includes at least 12 to 16 membrane-proximal residues, whereas nine or fewer residues did not
support this phenotype. One mechanism that could account for these
findings is that virus budding presumably requires significant
modification of the lipid environment at the site of assembly (or bud
site), such that membrane curvature is induced while the condensed
nucleocapsid-matrix complex associates with the inner leaflet of the
plasma membrane. It is conceivable that sequences in the
membrane-proximal region of envelope glycoproteins have been selected
to facilitate lipid reorganization either before or during the budding
event. Alternatively, the stem domain may associate the glycoprotein
with specific lipid types or membrane domains during transport. Since
virus budding involves the concerted action of both viral and cellular
components, the stem may also select for regions of the plasma membrane
that are competent for virus budding. Support for this suggestion comes
from immunofluorescence studies which revealed that GS-containing
glycoproteins (i.e., CD4-GS and HAG), but not those lacking GS sequence
(i.e., CD4, CD4-G, or HAG2), were localized in clusters or
blebs on the plasma membrane (unpublished observations). These regions
presumably represent sites of active virus budding, since matrix (M)
protein also appeared to be concentrated at these sites. To address
whether the restricted localization results from coalescence of viral
components by specific interactions exclusively or from some limitation
in the number or location of regions at the plasma membrane best suited
for efficient virus assembly will require additional studies using confocal microscopy where high-resolution optical sections of the bud
sites can be examined in greater detail. In any event, it is evident
that highly efficient virus budding of VSV virions is mediated by the
membrane-proximal G-stem domain through a concerted yet undefined
synergy with the condensed nucleocapsid-matrix protein complex.
To extend these observations further, we examined amino acid sequence
alignments of the membrane-proximal regions of several related
rhabdovirus glycoproteins, as well as of some heterologous viral
glycoproteins (Fig. 7). This analysis
revealed some intriguing features that may be important for the
assembly phenotype that we have observed. Among the vesiculoviruses,
this region is highly conserved; however, significant divergence is
seen when the analysis is extended to RV (a lyssavirus) and an
unclassified fish rhabdovirus. Yet there are characteristics within the
domains of these less-related glycoproteins that are absent from
glycoproteins (such as CD4 and influenza virus HA) that result in low
or basal levels of virus budding in the context of recombinant VSVs.
First, there are tryptophan residues located at position 6 and at
position 2 or 3 relative to the TM domain. These are reminiscent of
those found in the HIV-1 gp41 discussed above. Second, there are two hydrophobic residues located at positions 9 and/or 10. The tryptophans and the hydrophobic amino acids are not present in either the A/Japan
HA or CD4, both of which were not efficiently incorporated into the
recombinant VSVs and did not confer high-level virus budding, unless
appended to at least 12 to 16 residues of the G stem. It will be
interesting to determine if the introduction of these residues into the
analogous positions of the CD4 or HA stem region can confer high-level
budding of VSV.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 7.
Sequence alignment of the TM-ectodomain junction of VSV
G protein with analogous regions of related and unrelated type I
glycoproteins. Darkly shaded boxes indicate conserved tryptophan
residues within the membrane-proximal regions of the glycoprotein
ectodomains which are spaced either two or three residues and/or six
residues from the putative TM domain. Lightly shaded boxes indicate
hydrophobic residues positioned at either the third, fourth, or seventh
residue from the conserved tryptophans. A high degree of sequence
homology within their membrane-proximal regions is observed for related
vesiculovirus glycoproteins, whereas the glycoproteins of a fish
rhabdovirus (hemorrhagic septicemia virus, an unclassified
rhabdovirus), RV (a lyssavirus), ebola virus (a filovirus), and HIV-1
(a lentivirus) are similar to VSV G only in that these have a similar
spacing of tryptophan and hydrophobic residues at a conserved distance
from their TM domains.
|
|
We certainly cannot exclude the possibility that the VSV budding domain
in GS is responsible for localization of the glycoprotein within zones
of the plasma membrane where viral RNPs are actively budding. It is
possible that specificity of incorporation is dictated by a protein's
affinity for particular membrane lipids, which could potentially
explain lipid-type selectivity that results in distinct lipid
compositions of different viral envelopes (38). However, not
mutually exclusively, we favor a model in which the budding domain is
involved in recruitment of, or being recruited to, the condensed RNPs
underlying the plasma membrane during the initial stages of virus
budding. What remains to be tested is whether VSV budding occurs at
different sites at the plasma membrane when the GS budding domain is
present compared to when it is absent. In our most simplistic view, a
protein containing a VSV budding domain, which has the capacity to
synergize M protein-mediated particle budding, must therefore
contribute to its own incorporation into the VSV envelope.
 |
ACKNOWLEDGMENTS |
We greatly appreciate the generous gifts of the HA-G-encoding
cDNAs from Michael Roth (University of Texas Southwestern). We also
thank Robert Webster (St. Jude Children's Research Hospital) for the
kind gift of the HA-specific antisera and Lorraine Albritton (University of Tennessee
Memphis) for the 12CA5 hybridoma supernatant. CD4-specific antibodies were provided by the NIH AIDS Research and
Reference Reagent Program. We thank Jeetendra Eswaraka and Himangi
Jayakar for helpful comments on the manuscript. The technical assistance of Carolyn Matthews and Anne Timmerman is greatly
appreciated. Oligonucleotides were synthesized by the Molecular
Resource Center at University of Tennessee
Memphis.
This work was supported by NIH grant GM-53726 (to M.A.W.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Tennessee
Memphis, Memphis, TN 38163. Phone: (901) 448-4634. Fax: (901) 448-8462. E-mail: mwhitt{at}utmem.edu.
 |
REFERENCES |
| 1.
|
Bilsel, P.,
M. R. Castrucci, and Y. Kawaoka.
1993.
Mutations in the cytoplasmic tail of influenza A virus neuraminidase affect incorporation into virions.
J. Virol.
67:6762-6767[Abstract/Free Full Text].
|
| 2.
|
Campbell, M. J.
1995.
Lipofection reagents prepared by a simple ethanol injection technique.
BioTechniques
18:1027-1032[Medline].
|
| 3.
|
Chalfie, M.,
Y. Tu,
G. Euskirchen,
W. W. Ward, and D. C. Prasher.
1994.
Green fluorescent protein as a marker for gene expression.
Science
263:802-805[Abstract/Free Full Text].
|
| 4.
|
Chen, S. S.,
N. Ariel, and A. S. Huang.
1988.
Membrane anchors of vesicular stomatitis virus: characterization and incorporation into virions.
J. Virol.
62:2552-2556[Abstract/Free Full Text].
|
| 5.
|
Cheng, R. H.,
R. J. Kuhn,
N. H. Olson,
M. G. Rossmann,
H. K. Choi,
T. J. Smith, and T. S. Baker.
1995.
Nucleocapsid and glycoprotein organization in an enveloped virus.
Cell
80:621-630[CrossRef][Medline].
|
| 6.
|
Chong, L. D., and J. K. Rose.
1994.
Interactions of normal and mutant vesicular stomatitis virus matrix proteins with the plasma membrane and nucleocapsids.
J. Virol.
68:441-447[Abstract/Free Full Text].
|
| 7.
|
Craven, R. C.,
R. N. Harty,
J. Paragas,
P. Palese, and J. W. Wills.
1999.
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras.
J. Virol.
73:3359-3365[Abstract/Free Full Text].
|
| 8.
|
Delchambre, M.,
D. Gheysen,
D. Thines,
C. Thiriart,
E. Jacobs,
E. Verdin,
M. Horth,
A. Burny, and F. Bex.
1989.
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles.
EMBO J.
8:2653-2660[Medline].
|
| 9.
|
Garcia Sastre, A., and P. Palese.
1995.
Influenza virus vectors.
Biologicals
23:171-178[CrossRef][Medline].
|
| 10.
|
Garoff, H.,
R. Hewson, and D. J. E. Opstelten.
1998.
Virus maturation by budding.
Microbiol. Mol. Biol. Rev.
62:1171-1190[Abstract/Free Full Text].
|
| 11.
|
Gheysen, D.,
E. Jacobs,
F. de Foresta,
C. Thiriart,
M. Francotte,
D. Thines, and M. De Wilde.
1989.
Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells.
Cell
59:103-112[CrossRef][Medline].
|
| 12.
|
Harty, R. N.,
J. Paragas,
M. Sudol, and P. Palese.
1999.
A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding.
J. Virol.
73:2921-2929[Abstract/Free Full Text].
|
| 13.
|
Heim, R.,
A. B. Cubitt, and R. Y. Tsien.
1995.
Improved green fluorescence.
Nature
373:663-664[Medline].
|
| 14.
|
Januszeski, M. M.,
P. M. Cannon,
D. Chen,
Y. Rozenberg, and W. F. Anderson.
1997.
Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein.
J. Virol.
71:3613-3619[Abstract].
|
| 15.
|
Jin, H.,
G. P. Leser, and R. A. Lamb.
1994.
The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity.
EMBO J.
13:5504-5515[Medline].
|
| 16.
|
Jin, H.,
G. P. Leser,
J. Zhang, and R. A. Lamb.
1997.
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape.
EMBO J.
16:1236-1247[CrossRef][Medline].
|
| 17.
|
Johnson, J. E.,
M. J. Schnell,
L. Buonocore, and J. K. Rose.
1997.
Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.
J. Virol.
71:5060-5068[Abstract].
|
| 18.
|
Justice, P. A.,
W. Sun,
Y. Li,
Z. Ye,
P. R. Grigera, and R. R. Wagner.
1995.
Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus.
J. Virol.
69:3156-3160[Abstract].
|
| 19.
|
Kail, M.,
M. Hollinshead,
W. Ansorge,
R. Pepperkok,
R. Frank,
G. Griffiths, and D. Vaux.
1991.
The cytoplasmic domain of alphavirus E2 glycoprotein contains a short linear recognition signal required for viral budding.
EMBO J.
10:2343-2351[Medline].
|
| 20.
|
Kretzschmar, E.,
L. Buonocore,
M. J. Schnell, and J. K. Rose.
1997.
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
J. Virol.
71:5982-5989[Abstract].
|
| 21.
|
Lawson, N. D.,
E. A. Stillman,
M. A. Whitt, and J. K. Rose.
1995.
Recombinant vesicular stomatitis viruses from DNA.
Proc. Natl. Acad. Sci. USA
92:4477-4481[Abstract/Free Full Text].
|
| 22.
|
Lazarovits, J.,
S. P. Shia,
N. Ktistakis,
M. S. Lee,
C. Bird, and M. G. Roth.
1990.
The effects of foreign transmembrane domains on the biosynthesis of the influenza virus hemagglutinin.
J. Biol. Chem.
265:4760-4767[Abstract/Free Full Text].
|
| 23.
|
Lefrancois, L., and D. S. Lyles.
1982.
The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes.
Virology
121:168-174[CrossRef][Medline].
|
| 24.
|
Lopez, S.,
J. S. Yao,
R. J. Kuhn,
E. G. Strauss, and J. H. Strauss.
1994.
Nucleocapsid-glycoprotein interactions required for assembly of alphaviruses.
J. Virol.
68:1316-1323[Abstract/Free Full Text].
|
| 25.
|
McCallus, D. E.,
K. E. Ugen,
A. I. Sato,
W. V. Williams, and D. B. Weiner.
1992.
Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule.
Viral Immunol.
5:163-172[Medline].
|
| 26.
|
Mebatsion, T., and K. K. Conzelmann.
1996.
Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein.
Proc. Natl. Acad. Sci. USA
93:11366-11370[Abstract/Free Full Text].
|
| 27.
|
Mebatsion, T.,
S. Finke,
F. Weiland, and K. K. Conzelmann.
1997.
A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells.
Cell
90:841-847[CrossRef][Medline].
|
| 28.
|
Mebatsion, T.,
M. Konig, and K. K. Conzelmann.
1996.
Budding of rabies virus particles in the absence of the spike glycoprotein.
Cell
84:941-951[CrossRef][Medline].
|
| 29.
|
Metsikko, K., and K. Simons.
1986.
The budding mechanism of spikeless vesicular stomatitis virus particles.
EMBO J.
5:1913-1920[Medline].
|
| 30.
|
Naim, H. Y., and M. G. Roth.
1993.
Basis for selective incorporation of glycoproteins into the influenza virus envelope.
J. Virol.
67:4831-4841[Abstract/Free Full Text].
|
| 31.
|
Oomens, A. G., and G. W. Blissard.
1999.
Requirement for GP64 to drive efficient budding of Autographa californica multicapsid nucleopolyhedrovirus.
Virology
254:297-314[CrossRef][Medline].
|
| 32.
|
Owen, K. E., and R. J. Kuhn.
1997.
Alphavirus budding is dependent on the interaction between the nucleocapsid and hydrophobic amino acids on the cytoplasmic domain of the E2 envelope glycoprotein.
Virology
230:187-196[CrossRef][Medline].
|
| 33.
|
Park, E. K.,
M. R. Castrucci,
A. Portner, and Y. Kawaoka.
1998.
The M2 ectodomain is important for its incorporation into influenza A virions.
J. Virol.
72:2449-2455[Abstract/Free Full Text].
|
| 34.
|
Perez, L. G.,
G. L. Davis, and E. Hunter.
1987.
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions.
J. Virol.
61:2981-2988[Abstract/Free Full Text].
|
| 35.
|
Rose, J. K.,
L. Buonocore, and M. A. Whitt.
1991.
A new cationic liposome reagent mediating nearly quantitative transfection of animal cells.
BioTechniques
10:520-525[Medline].
|
| 36.
|
Roth, M. G.,
C. Doyle,
J. Sambrook, and M. J. Gething.
1986.
Heterologous transmembrane and cytoplasmic domains direct functional chimeric influenza virus hemagglutinins into the endocytic pathway.
J. Cell Biol.
102:1271-1283[Abstract/Free Full Text].
|
| 37.
|
Salzwedel, K.,
J. T. West, and E. Hunter.
1999.
A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.
J. Virol.
73:2469-2480[Abstract/Free Full Text].
|
| 38.
|
Scheiffele, P.,
A. Rietveld,
T. Wilk, and K. Simons.
1999.
Influenza viruses select ordered lipid domains during budding from the plasma membrane.
J. Biol. Chem.
274:2038-2044[Abstract/Free Full Text].
|
| 39.
|
Schnell, M. J.,
L. Buonocore,
E. Boritz,
H. P. Ghosh,
R. Chernish, and J. K. Rose.
1998.
Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus.
EMBO J.
17:1289-1296[CrossRef][Medline].
|
| 40.
|
Schnell, M. J.,
L. Buonocore,
E. Kretzschmar,
E. Johnson, and J. K. Rose.
1996.
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.
Proc. Natl. Acad. Sci. USA
93:11359-11365[Abstract/Free Full Text].
|
| 41.
|
Schnell, M. J.,
J. E. Johnson,
L. Buonocore, and J. K. Rose.
1997.
Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection.
Cell
90:849-857[CrossRef][Medline].
|
| 42.
|
Stillman, E. A.,
J. K. Rose, and M. A. Whitt.
1995.
Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins.
J. Virol.
69:2946-2953[Abstract].
|
| 43.
|
Suomalainen, M.,
P. Liljestrom, and H. Garoff.
1992.
Spike protein-nucleocapsid interactions drive the budding of alphaviruses.
J. Virol.
66:4737-4747[Abstract/Free Full Text].
|
| 44.
|
Takada, A.,
C. Robison,
H. Goto,
A. Sanchez,
K. G. Murti,
M. A. Whitt, and Y. Kawaoka.
1997.
A system for functional analysis of Ebola virus glycoprotein.
Proc. Natl. Acad. Sci. USA
94:14764-14769[Abstract/Free Full Text].
|
| 45.
|
Thomas, D.,
W. W. Newcomb,
J. C. Brown,
J. S. Wall,
J. F. Hainfeld,
B. L. Trus, and A. C. Steven.
1985.
Mass and molecular composition of vesicular stomatitis virus: a scanning transmission electron microscopy analysis.
J. Virol.
54:598-607[Abstract/Free Full Text].
|
| 46.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus Gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 47.
|
Yu, X.,
X. Yuan,
M. F. McLane,
T. H. Lee, and M. Essex.
1993.
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions.
J. Virol.
67:213-221[Abstract/Free Full Text].
|
Journal of Virology, March 2000, p. 2239-2246, Vol. 74, No. 5
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wirblich, C., Tan, G. S., Papaneri, A., Godlewski, P. J., Orenstein, J. M., Harty, R. N., Schnell, M. J.
(2008). PPEY Motif within the Rabies Virus (RV) Matrix Protein Is Essential for Efficient Virion Release and RV Pathogenicity. J. Virol.
82: 9730-9738
[Abstract]
[Full Text]
-
Vishwanathan, S. A., Hunter, E.
(2008). Importance of the Membrane-Perturbing Properties of the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 gp41 to Viral Fusion. J. Virol.
82: 5118-5126
[Abstract]
[Full Text]
-
Swinteck, B. D., Lyles, D. S.
(2008). Plasma Membrane Microdomains Containing Vesicular Stomatitis Virus M Protein Are Separate from Microdomains Containing G Protein and Nucleocapsids. J. Virol.
82: 5536-5547
[Abstract]
[Full Text]
-
Westenberg, M., Vlak, J. M.
(2008). GP64 of group I nucleopolyhedroviruses cannot readily rescue infectivity of group II f-null nucleopolyhedroviruses. J. Gen. Virol.
89: 424-431
[Abstract]
[Full Text]
-
Zhou, J., Blissard, G. W.
(2008). Display of Heterologous Proteins on gp64null Baculovirus Virions and Enhanced Budding Mediated by a Vesicular Stomatitis Virus G-Stem Construct. J. Virol.
82: 1368-1377
[Abstract]
[Full Text]
-
Rojek, J. M., Perez, M., Kunz, S.
(2008). Cellular Entry of Lymphocytic Choriomeningitis Virus. J. Virol.
82: 1505-1517
[Abstract]
[Full Text]
-
Klingen, Y., Conzelmann, K.-K., Finke, S.
(2008). Double-Labeled Rabies Virus: Live Tracking of Enveloped Virus Transport. J. Virol.
82: 237-245
[Abstract]
[Full Text]
-
Perez, M., Clemente, R., Robison, C. S., Jeetendra, E., Jayakar, H. R., Whitt, M. A., de la Torre, J. C.
(2007). Generation and Characterization of a Recombinant Vesicular Stomatitis Virus Expressing the Glycoprotein of Borna Disease Virus. J. Virol.
81: 5527-5536
[Abstract]
[Full Text]
-
Mittler, E., Kolesnikova, L., Strecker, T., Garten, W., Becker, S.
(2007). Role of the Transmembrane Domain of Marburg Virus Surface Protein GP in Assembly of the Viral Envelope. J. Virol.
81: 3942-3948
[Abstract]
[Full Text]
-
Irie, T., Shimazu, Y., Yoshida, T., Sakaguchi, T.
(2007). The YLDL Sequence within Sendai Virus M Protein Is Critical for Budding of Virus-Like Particles and Interacts with Alix/AIP1 Independently of C Protein. J. Virol.
81: 2263-2273
[Abstract]
[Full Text]
-
Codran, A., Royer, C., Jaeck, D., Bastien-Valle, M., Baumert, T. F., Kieny, M. P., Pereira, C. A., Martin, J.-P.
(2006). Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J. Gen. Virol.
87: 2583-2593
[Abstract]
[Full Text]
-
McCown, M. F., Pekosz, A.
(2006). Distinct domains of the influenza a virus m2 protein cytoplasmic tail mediate binding to the m1 protein and facilitate infectious virus production.. J. Virol.
80: 8178-8189
[Abstract]
[Full Text]
-
Makela, A. R., Matilainen, H., White, D. J., Ruoslahti, E., Oker-Blom, C.
(2006). Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides.. J. Virol.
80: 6603-6611
[Abstract]
[Full Text]
-
Zimmer, G., Bossow, S., Kolesnikova, L., Hinz, M., Neubert, W. J., Herrler, G.
(2005). A Chimeric Respiratory Syncytial Virus Fusion Protein Functionally Replaces the F and HN Glycoproteins in Recombinant Sendai Virus. J. Virol.
79: 10467-10477
[Abstract]
[Full Text]
-
Perez, M., de la Torre, J. C.
(2005). Identification of the Borna disease virus (BDV) proteins required for the formation of BDV-like particles. J. Gen. Virol.
86: 1891-1895
[Abstract]
[Full Text]
-
Hanika, A., Larisch, B., Steinmann, E., Schwegmann-Wessels, C., Herrler, G., Zimmer, G.
(2005). Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol.
86: 1455-1465
[Abstract]
[Full Text]
-
Martinez, I., Wertz, G. W.
(2005). Biological Differences between Vesicular Stomatitis Virus Indiana and New Jersey Serotype Glycoproteins: Identification of Amino Acid Residues Modulating pH-Dependent Infectivity. J. Virol.
79: 3578-3585
[Abstract]
[Full Text]
-
Abada, P., Noble, B., Cannon, P. M.
(2005). Functional Domains within the Human Immunodeficiency Virus Type 2 Envelope Protein Required To Enhance Virus Production. J. Virol.
79: 3627-3638
[Abstract]
[Full Text]
-
Licata, J. M., Johnson, R. F., Han, Z., Harty, R. N.
(2004). Contribution of Ebola Virus Glycoprotein, Nucleoprotein, and VP24 to Budding of VP40 Virus-Like Particles. J. Virol.
78: 7344-7351
[Abstract]
[Full Text]
-
Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Moller, P., Wagner, R., Volchkov, V., Klenk, H.-D., Feldmann, H., Stroher, U.
(2004). Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses. J. Virol.
78: 5458-5465
[Abstract]
[Full Text]
-
Jeetendra, E., Ghosh, K., Odell, D., Li, J., Ghosh, H. P., Whitt, M. A.
(2003). The Membrane-Proximal Region of Vesicular Stomatitis Virus Glycoprotein G Ectodomain Is Critical for Fusion and Virus Infectivity. J. Virol.
77: 12807-12818
[Abstract]
[Full Text]
-
Saez-Cirion, A., Arrondo, J. L. R., Gomara, M. J., Lorizate, M., Iloro, I., Melikyan, G., Nieva, J. L.
(2003). Structural and Functional Roles of HIV-1 gp41 Pretransmembrane Sequence Segmentation. Biophys. J
85: 3769-3780
[Abstract]
[Full Text]
-
Brown, E. L., Lyles, D. S.
(2003). Organization of the Vesicular Stomatitis Virus Glycoprotein into Membrane Microdomains Occurs Independently of Intracellular Viral Components. J. Virol.
77: 3985-3992
[Abstract]
[Full Text]
-
Neumann, G., Whitt, M. A., Kawaoka, Y.
(2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol.
83: 2635-2662
[Abstract]
[Full Text]
-
Jeetendra, E., Robison, C. S., Albritton, L. M., Whitt, M. A.
(2002). The Membrane-Proximal Domain of Vesicular Stomatitis Virus G Protein Functions as a Membrane Fusion Potentiator and Can Induce Hemifusion. J. Virol.
76: 12300-12311
[Abstract]
[Full Text]
-
Waning, D. L., Schmitt, A. P., Leser, G. P., Lamb, R. A.
(2002). Roles for the Cytoplasmic Tails of the Fusion and Hemagglutinin-Neuraminidase Proteins in Budding of the Paramyxovirus Simian Virus 5. J. Virol.
76: 9284-9297
[Abstract]
[Full Text]
-
Maillard, A. P., Gaudin, Y.
(2002). Rabies virus glycoprotein can fold in two alternative, antigenically distinct conformations depending on membrane-anchor type. J. Gen. Virol.
83: 1465-1476
[Abstract]
[Full Text]
-
Noda, T., Sagara, H., Suzuki, E., Takada, A., Kida, H., Kawaoka, Y.
(2002). Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP. J. Virol.
76: 4855-4865
[Abstract]
[Full Text]
-
Harty, R. N., Brown, M. E., McGettigan, J. P., Wang, G., Jayakar, H. R., Huibregtse, J. M., Whitt, M. A., Schnell, M. J.
(2001). Rhabdoviruses and the Cellular Ubiquitin-Proteasome System: a Budding Interaction. J. Virol.
75: 10623-10629
[Abstract]
[Full Text]
-
Perez, M., Watanabe, M., Whitt, M. A., de la Torre, J. C.
(2001). N-Terminal Domain of Borna Disease Virus G (p56) Protein Is Sufficient for Virus Receptor Recognition and Cell Entry. J. Virol.
75: 7078-7085
[Abstract]
[Full Text]
-
Mangor, J. T., Monsma, S. A., Johnson, M. C., Blissard, G. W.
(2001). A GP64-Null Baculovirus Pseudotyped with Vesicular Stomatitis Virus G Protein. J. Virol.
75: 2544-2556
[Abstract]
[Full Text]
-
Jayakar, H. R., Murti, K. G., Whitt, M. A.
(2000). Mutations in the PPPY Motif of Vesicular Stomatitis Virus Matrix Protein Reduce Virus Budding by Inhibiting a Late Step in Virion Release. J. Virol.
74: 9818-9827
[Abstract]
[Full Text]